A Study of Bevacizumab to Prevent Malignant Ascites

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Malignant Ascites
Interventions
DRUG

Bevacizumab

Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.

Trial Locations (3)

77030

Baylor College of Medicine, Houston

Ben Taub General Hospital, Houston

Michael E. DeBakey Veterans Affairs Medical Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Baylor College of Medicine

OTHER